Effect of Whole Grain Diet on Non-Alcoholic Fatty Liver

The effect of a diet enriched with whole grains or bran-contained cereals on liver echogenicity, liver function markers, anthropometry, insulin resistance, blood pressure and lipid profile in patients with nonalcoholic fatty liver disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170206032417N3

Enrollment

Registered

2017-12-27

Start date

2017-06-24

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: In this study, people in the intervention group after become aware of foods that are considered as whole grains,for 3 months will change their daily intake of cerea

Treatment - Other

Intervention group: In this study, people in the intervention group after become aware of foods that are considered as whole grains,for 3 months will change their daily intake of cereals from refined

Control group: In this study, individuals in the control group were asked to take their usual daily intake of cereals for 3 months and not to change their physical activity.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age range over 18 years old in both sexes Non-alcoholic fatty liver disease detected by ultrasound

Exclusion criteria

Exclusion criteria: Alcohol consumption or history Positive serology-hepatitis A-B-C Pregnancy and lactation during the study Diabetes Hypothyroidism Psychopathy kidney Diseases People who regularly receive at least half the daily cereals they consume from whole grains A major change in lifestyle

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: At weeks 0,12. Method of measurement: Scale, kg.;Triglyceride. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg\dl.;Total cholesterol. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, mg\dl.;LDL cholesterol. Timepoint: At weeks 0 ,12. Method of measurement: (LDL= Total cholestrol – (HDL+ TG/5)).;HDL cholesterol. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, mg\dl.;Fasting blood sugar. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, mg\dl.;Serum insulin. Timepoint: At weeks 0,12. Method of measurement: Radioimmunoassay.;Alanine Aminotransferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, IU\ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU\ Lit.;Gamma Glutamyl transferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method , IU\ Lit.;Hepatic steatosis. Timepoint: Before intervention and three months intervention. Method of measurement: Ultrasonography.;Systolic blood pressure. Timepoint: At weeks 0 ,12. Method of measurement: Mercury sphygmomanometer, mmhg.;Diastolic blood pressure. Timepoint: At weeks 0, 12. Method of measurement: Mercury sphygmomanometer, mmhg.;Height. Timepoint: Before intervention. Method of measurement: Stadiometer, mm.;Body mass index. Timepoint: At weeks 0 ,12. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.	—

Measure

Time frame

Weight. Timepoint: At weeks 0,12. Method of measurement: Scale, kg.;Triglyceride. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, mg\dl.;Total cholesterol. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, mg\dl.;LDL cholesterol. Timepoint: At weeks 0 ,12. Method of measurement: (LDL= Total cholestrol – (HDL+ TG/5)).;HDL cholesterol. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, mg\dl.;Fasting blood sugar. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, mg\dl.;Serum insulin. Timepoint: At weeks 0,12. Method of measurement: Radioimmunoassay.;Alanine Aminotransferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method, IU\ Lit.;Aspartat transaminase. Timepoint: At weeks 0, 12. Method of measurement: Enzymatic method, IU\ Lit.;Gamma Glutamyl transferase. Timepoint: At weeks 0,12. Method of measurement: Enzymatic method , IU\ Lit.;Hepatic steatosis. Timepoint: Before intervention and three months intervention. Method of measurement: Ultrasonography.;Systolic blood pressure. Timepoint: At weeks 0 ,12. Method of measurement: Mercury sphygmomanometer, mmhg.;Diastolic blood pressure. Timepoint: At weeks 0, 12. Method of measurement: Mercury sphygmomanometer, mmhg.;Height. Timepoint: Before intervention. Method of measurement: Stadiometer, mm.;Body mass index. Timepoint: At weeks 0 ,12. Method of measurement: Weight(kg)\[height(m)]2 , kg\m2.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohammad Alizadeh

Oroumia University of Medical Sciences

alizadeh.m@umsu.ac.ir+98 44 3275 2375

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026